Recent Updates
Recently added Catalysts
ANGO Positive Sentiment

AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer

Key Takeaway: AngioDynamics has announced the appointment of Eric Honroth as its new President and CEO, effective November 2, 2026. He will succeed Jim Clemmer, who is leaving the Board of Directors. This leadership change is expected to guide the company in its mission to improve patient care and expand treatment options.

Market Sentiment Analysis

POSITIVE FACTORS

  • Appointment of a new CEO indicates strategic leadership change.
  • Eric Honroth brings experience to enhance company growth.
  • Focus on improving patient care and expanding treatment options.

Full Press Release Details

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Eric Honroth as President and Chief Executive Officer and a member of the Board of Directors, effective November 2, 2026. Mr. Honroth will succeed Jim Clemmer, who will depart the Board on N

Frequently Asked Questions

Who is the new CEO of AngioDynamics?

Eric Honroth has been appointed as the new CEO of AngioDynamics.

When will Eric Honroth start as CEO?

Eric Honroth will officially take over as CEO on November 2, 2026.

Who did Eric Honroth replace as CEO?

He will succeed Jim Clemmer, who is leaving the Board of Directors.

What is AngioDynamics focused on?

AngioDynamics focuses on restoring blood flow, expanding cancer treatment options, and improving patient quality of life.

Last updated: Oct 8, 2026